title: Arrays of High-Aspect Ratio Microchannels for High-Throughput Isolation of Circulating Tumor Cells (CTCs).
abstract: Microsystem-based technologies are providing new opportunities in the area of in vitro diagnostics due to their ability to provide process automation enabling point-of-care operation. As an example, microsystems used for the isolation and analysis of circulating tumor cells (CTCs) from complex, heterogeneous samples in an automated fashion with improved recoveries and selectivity are providing new opportunities for this important biomarker. Unfortunately, many of the existing microfluidic systems lack the throughput capabilities and/or are too expensive to manufacture to warrant their widespread use in clinical testing scenarios. Here, we describe a disposable, all-polymer, microfluidic system for the high-throughput (HT) isolation of CTCs directly from whole blood inputs. The device employs an array of high aspect ratio (HAR), parallel, sinusoidal microchannels (25 µm × 150 µm; W × D; AR = 6.0) with walls covalently decorated with anti-EpCAM antibodies to provide affinity-based isolation of CTCs. Channel width, which is similar to an average CTC diameter (12-25 µm), plays a critical role in maximizing the probability of cell/wall interactions and allows for achieving high CTC recovery. The extended channel depth allows for increased throughput at the optimized flow velocity (2 mm/s in a microchannel); maximizes cell recovery, and prevents clogging of the microfluidic channels during blood processing. Fluidic addressing of the microchannel array with a minimal device footprint is provided by large cross-sectional area feed and exit channels poised orthogonal to the network of the sinusoidal capillary channels (so-called Z-geometry). Computational modeling was used to confirm uniform addressing of the channels in the isolation bed. Devices with various numbers of parallel microchannels ranging from 50 to 320 have been successfully constructed. Cyclic olefin copolymer (COC) was chosen as the substrate material due to its superior properties during UV-activation of the HAR microchannels surfaces prior to antibody attachment. Operation of the HT-CTC device has been validated by isolation of CTCs directly from blood secured from patients with metastatic prostate cancer. High CTC sample purities (low number of contaminating white blood cells, WBCs) allowed for direct lysis and molecular profiling of isolated CTCs.
authors.affiliation: Department of Biomedical Engineering, University of North Carolina, Chapel Hill, NC, USA ; BioFluidica, Inc., Chapel Hill, NC, USA.
authors.forename: Mateusz L
authors.initials: ML
authors.lastname: Hupert
authors.affiliation: Department of Chemistry, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: Joshua M
authors.initials: JM
authors.lastname: Jackson
authors.affiliation: Department of Biomedical Engineering, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: Hong
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Biomedical Engineering, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: Małgorzata A
authors.initials: MA
authors.lastname: Witek
authors.affiliation: Department of Chemistry, Louisiana State University, Baton Rouge, LA, USA.
authors.forename: Joyce
authors.initials: J
authors.lastname: Kamande
authors.affiliation: Lineberger Comprehensive Cancer Center, UNC School of Medicine, Chapel Hill, NC, USA.
authors.forename: Matthew I
authors.initials: MI
authors.lastname: Milowsky
authors.affiliation: Lineberger Comprehensive Cancer Center, UNC School of Medicine, Chapel Hill, NC, USA.
authors.forename: Young E
authors.initials: YE
authors.lastname: Whang
authors.affiliation: Department of Biomedical Engineering, University of North Carolina, Chapel Hill, NC, USA ; Department of Chemistry, University of North Carolina, Chapel Hill, NC, USA ; Lineberger Comprehensive Cancer Center, UNC School of Medicine, Chapel Hill, NC, USA ; BioFluidica, Inc., Chapel Hill, NC, USA.
authors.forename: Steven A
authors.initials: SA
authors.lastname: Soper